ETON News and Press, Eton Pharmaceutcials Inc. From 11/09/23

Eton Pharmaceuticals Inc. (ETON) is expected to report $-0.1 for Q3 2023

DEER PARK, Ill., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced that it will report th...

-- Expect Q1 2024 product launch -- -- Nitisinone market estimated to be more than $50 million annually -- -- Eton will offer Eton Cares support program to all patients -- DEER PARK, Ill., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company&...

2023-09-11 15:29:20 ET Summary Eton Pharmaceuticals, Inc. is a small specialty pharmaceutical company whose main product ALKINDI SPRINKLE is gaining market share. The stock has doubled since reporting second quarter results one month ago. Can the rally continue? An invest...

2023-09-06 10:00:10 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...

DEER PARK, Ill., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, will present at the H.C. Wainwri...

2023-08-11 10:14:56 ET Gainers: Eton Pharmaceuticals ( ETON ) +23% . Semler Scientific ( SMLR ) +20% . ModivCare ( MODV ) +15% . Erasca ( ERAS ) +9% . Relmada Therapeutics ( RLMD ) +8% . Losers: Cano Health ( CANO ) -...

2023-08-10 20:32:07 ET Eton Pharmaceuticals, Inc. (ETON) Q2 2023 Earnings Conference Call August 10, 2023, 04:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - CEO James Gruber - CFO Conference Call Participants Rag...

2023-08-10 16:42:06 ET Eton Pharmaceuticals press release ( NASDAQ: ETON ): Q2 GAAP EPS of $0.18. Revenue of $12M (+62.2% Y/Y). For further details see: Eton Pharmaceuticals GAAP EPS of $0.18, revenue of $12M

Total Q2 revenue of $12.0 million and net income of $4.6 million Product sales and royalty revenue of $6.5 million up 175% from Q2 2022 and 22% from Q1 2023 $21.6 million of cash on hand Launched Betaine Anhydrous Management to hold conference call today at 4:30pm ET DEER ...